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ABSTRACT : For active cancer immunotherapy by alveolar macrophage (AM) 
targeting, the usefulness of polysaccharide-coated liposomes was examined in an 
animal model, and the morphological changes in activated AM were observed using 
scanning electron microscopy. Among the liposomes tested, cholesterol-mannan-
coated large unilamellar liposomes (CHM-LUV) had the highest targetability to the 
lung. MDP-L18 or MA-CDA as synthetic immunoactivators, were encapsulated with-
in CHM-LUV. After the intravenous injection of encapsulated or nonencapsulated, 
MA-CDA or MDP-L18, the antitumor activity of C57BL/6 AM against Lewis lung 
carcinoma (3LL) was measured in vitro. The encapsulated immunoactivators 
enhanced the antitumor activity of AM more effectively and for a longer time than 
the nonencapsulated ones. Concurrent with activation by MA-CDA, AM showed 
signs of very high surface activity, such as prominent ruffles, elongated filopodia 
and thickened lamellipodia. Some of the AM showed strong attachment to 3LL cells 
in vitro. No prolonged survival was obtained with the treatment of 3LL-bearing 
mice by CHM-LUV (MA-CDA) alone. However, these date demonstrated that poly-
saccharide-coated liposomes containing immunoactivator might be useful in future 
active cancer immunotherapy by AM targeting.
      INTRODUCTION 
Immune cells, such as macrophages, killer
T-cells and natural killer cells, play important 
roles in cancer treatment. Active immuno-
therapy procedures that enhance the antitumor 
activity of these cells have been studied. For
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effective immunotherapy procedures, many 
investigators have developed immunoactiva-
tors which can specifically activate these cells 
while leaving the host unharmed, and methods 
of their administration have been studied (1). 
 Liposomes as convenient drug carriers in the 
treatment of cancer and infectious diseases 
have been investigated in many laboratories (2, 
3 ), and a few clinical applications of lipo-
somes have been reported (4, 5 ). In the 
treatment of cancer, antitumor agents or 
immunoactivators have been encapsulated in 
liposomes, and successful results have been 
reported in animal models (6-9). SUNAMOTO et 
al. developed polysaccharide-coated liposomes, 
which were more stable against external 
stimuli in blood than conventional liposomes 
and had specific organ targetability (10, 11). 
 In the present study, the usefulness of poly-
saccharide-coated liposomes for active cancer 
immunotherapy by alveolar macrophages (AM) 
targeting was examined, and the surface 
activity of activated AM using scanning 
electron microscopy was also observed. 
   MATERIALS AND METHODS 
 Animals. Specific-pathogen-free male C57 
BL/6 mice, five to seven weeks old, were ob-
tained from Charles River Japan Inc. Mice 
were fed in a clean house at Nagasaki Univer-
sity Laboratory Animal Center. 
 Cell Cultures and Reagents. The syngeneic 
tumor, Lewis lung carcinoma (3LL ), was a 
gift from Chugai Pharmaceutical Co., Japan, 
and maintained in CRPMI. The AM-mediated 
cytotoxicity and cytostasis assay were always 
carried out with 3LL in the exponential 
growth phase. All cells were incubated at 37°C 
in a humidified atmosphere containing 5% CO2 
in CRPMI. 
 MDP-L18, a MDP derivative, was a gift 
from Daiichi Pharmaceutical Co., Japan. MA-
CDA, a synthetic polyanion, was a gift from 
Raphael M. OTTENBRITE (Virginia Common-
wealth University, Richmond, Virginia, U.S. 
A. ), who has synthesized a large number of 
polyanions and examined their antitumor 
activities (12). Among these synthetic polyan-
ions, MA-CDA has notably high antitumor
 activity ; its structure is shown in Fig. 1. 
MA-CDA=poly (maleic acid-alt-
            2-cyclohexyl-1, 3-dioxep-5-ene)
Fig. 1. The structure of MA-CDA.
 Preparation of AM. AM were harvested by 
a tracheobronchial lavage method (13). Mice 
were anesthetized with an intraperitoneal 
injection of pentobarbital sodium, and 
swabbed with iodine in an airflow hood. After 
opening the peritoneal cavity, mice were 
exsanguinated by cardiac puncture. The 
trachea was cannulated with an intravenous 
catheter (ATOM, Inc., Tokyo ) after thor-
acotomy. The lungs were lavaged with 0.5-0.7 
ml of Cat +- and Mgt +- free PBS at 4C, and 
five to seven ml of lavage fluid was recovered 
per mouse. Five lavage fluid samples were 
pooled and washed twice by centrifugation at 
4'C for 10 min at 260g ; the cell pellet was 
resuspended in CRPMI. Then, viability counts 
and characterization of AM were performed. 
The harvested cells were found to be more than 
95% viable by trypan blue dye exclusion, and 
composed of more than 96% AM on the basis 
of nonspecific esterase staining and mor-
phology. Then, 2 X 105 or 1 X 105 harvested cells 
were plated in each well of a Falcon microtiter 
plate (No. 3040, Oxnard, Calif. ). After a 60-
min incubation, plated cells were gently 
washed twice by filling the wells with CRPMI 
to eliminate nonadherent cells containing 
neutrophils and small mononuclear cells. The 
mean number of nonadherent cells per well was 
less than 10 % of initial plated cells in 10 
experiments. 
 Preparation of Liposomes. CHM-coated 
liposomes, as one type of polysaccharide-
coated liposomes, were prepared by the method
   reported by Junzo Sunamoto (10, 11). In addit-
   ion, LUV containing MA-CDA in the interior 
    core were prepared by the same procedure as 
   that reported by Szoka, et al (14, 15). In order 
   to study in vivo uptake of liposomes by AM, 
   MLV were labeled with a lipophilic fluorescent 
   probe (terbium triacetylacetate, Tb (acac)3) 
   which was donated by L. Varallino (Virginia 
   Commonwealth University, Richmond, Vir-
    inia, U.S.A.). 
     In Vivo Uptake of Liposomes by AM. The 
   cells (AM>96%), harvested by lavage 1 or 24 
   h after intravenous injection of terbium-
   labeled CHM-MLV, were resuspended in PBS 
   containing 10% FCS, and cytocentrifuge 
    smears stained with May-Giemsa's stain were 
    prepared. Fluorescence of AM was then 
    observed by fluorescence microscopy with 
   ultraviolet excitation, and photographed. 
     In Vivo Activation of AM by Immunoactiva-
   tors (MDP-L 18 or MA-CDA ). Mice were 
    injected intravenously with either nonenca-
    psulated immunoactivator, or immuno-
   activator or PBS encapsulated within CHM-
   LUV. A control group of mice were injected 
   with PBS. The CHM-LUV were suspended in a 
   volume of 0.2 ml PBS. AM were harvested at
   various times after injection, and their tumor
   cytotoxic properties were assayed in vitro as 
   follows. 
     The statistically significant differences 
    between groups was determined by paired 
   Student's t test. 
     AM-mediated Cytotoxicity Assay. AM-
    mediated cytotoxicity was measured in an 
    18h 51Cr release assay. Briefly, samples of 104 
   target cells (3LL) prelabeled with [51Cr] Nat 
   Cr 04 (lmCi/ml) for one hour were added to 
   triplicate wells containing 1 X 105 AM or to 
    empty control wells. The mixtures were
   incubated at 37°C for 18h, and then radioactivi-
    ties of aliquots of the supernatant were 
    counted in a gamma-counter. Maximum 
   release was determined by lysis of the tumor 
   cells with 1N HC1. The cytotoxic activity of 
   AM was calculated using the following
   formula : % cytotoxicity
cpm(activated AM+3LL) -
cpm(maximum release) -
         cpm(untreated AM + 3LL) X 100 
         cpm(untreated AM+3LL)
 AM-mediated Cytostasis Assay. After the 
preparation of AM monolayers described 
above, target cells ( 3LL ) were added to 
triplicate wells containing AM or to empty 
control wells. Plates were incubated for 48 h, 
and 0.1 ,u Ci [3H ] thymidine (15.1 Ci/mmol ; 
New England Nuclear, Boston, Mass., U.S.A. ) 
was added to the wells 16 h before culture 
completion. 
 After 48-h incubation, cells were harvested 
on a glass filter using a Labo Mash multiple 
cell harvester (Labo Science Co., Tokyo). The 
radioactivity of [3H] thymidine incorporated 
into 3LL was measured by liquid scintillation. 
The cytostatic activity of AM was calculated 
using the following formula :
 cytostasis-_cpm(3LL alone)- cpm(AM+3LL) X 100 
                cpm(3LL alone)
 Preparation of Specimens for Scanning 
Electron Microscopic Examination. AM (1 X 
105 /well) were plated onto 5-mm-diameter 
glass coverslips placed in wells of a Microtest 
III plate. In order to study the interaction 
between AM and target cells, 1 X 104 3LL were 
added to AM, incubated for 24 h, and vigorous-
ly washed twice with CRPMI. The coverslips 
were fixed in 1% glutaraldehyde for one hour, 
rinsed twice with PBS, and postfixed in 1 % 
osmium tetroxide at 4°C for 1 h. The samples 
were dehydrated with a graded series of 
ethanol and isoamylacetate. They were then 
critical-point dried in a Polaron E 3000 criti-
calpoint drier, coated with gold-palladium, 
and examined with a JEOL JEM-100CX elec-
tron microscope (JEOL Ltd., Japan) at 10 kV. 
 Trial in Treatment of Tumor-Bearing Mice 
by CHM-LUV(MA-CDA). C57BL/6 mice were 
injected subcutaneously in the footpad with 
1 X 105 viable 3LL tumor cells suspended in 0.05 
ml of PBS. Approximately two weeks later, 
when the tumors reached about 10 mm in 
diameter, microscopic pulmonary metastases 
were observed in most of the mice (data not 
shown).
  CHM-LUV (MA-CDA) treatment was done 
at five, eight, and 11 days after the inocula-
tion of tumor to inhibit pulmonary metastasis. 
At 12 days post-inoculation, the mice were 
anesthetized by pentobarbital sodium and the 
tumor-bearing leg (primary tumor ) was 
amputated at midfemur. Treatment of lipos-
omes consisted of a tail vein injection of CHM-
LUV suspended in 0.2 ml of PBS. The CHM-
LUV contained either MA-CDA (1000 ,u g per 
mouse) or PBS. Additional controls included 
mice injected intravenousely with tree MA-CD 
A (1000ag per mouse) or PBS. 
  Survival rate in each treatment groups was 
calculated according to the method of Kaplan 
and Meier (16) . 
          RESULTS 
 Uptake of MLV by AM. AM harvested by 
pulmonary lavage were examined by fluores-
cent microscopy to determine whether AM had 
phagocytized CHM-MLV circulating in the 
peripheral blood. AM were harvested one or 24 
h after intravenous injection of terbium-labeled 
CHM-MLV. The labeled CHM-MLV were 
engulfed within the cytoplasm of AM, and 
there was a difference in the number of 
cytoplasmic fluorescent foci among AM (Figs. 
2, 3). There were also many AM which had no 
cytoplasmic fluorescent foci (data not shown). 
 In Vivo Activation of AM by MDP-L18. As 
LUV are usually able to contain a larger 
amount of drug than MLV, LUV were used in 
the experiment. CHM-LUV accumulate in the 
lung more efficiently than conventional LUV 
after intravenous injection. 
 Mice were injected intravenously with 
different doses of MDP-L 18, either nonen-
capsulated or encapsulated within liposomes, 
ranging from 0.01 to 100 ,u g per mouse. CHM-
LUV (MDP-L 18) led to a higher cytotoxic activ-
ity in AM than free MDP-L 18 at any dosage. 
A particularly significant increase in cytoto-
xicity was observed in the liposomes contain-
ing more than 1,u g of MDP-L 18, and maximal 
activation of AM was obtained in the lipo-
somes containing 10,ug of MDP-L 18 (Fig. 4). 
 Next, AM were harvested four, six, 12, 24, 
48 and 72 h after intravenous injection of
Fig. 2. Fluorescence micrograph of AM harvest-
       ed one hour after intravenous injection 
      of CHM-MLV labeled with terbium ; 
       exposure time 1'00". X400.
Fig. 3. Fluorescence micrograph of AM harvest-
      ed 24h after intravenous injection of 
      CHM-MLV labeled with terbium ; 
       exposure time 3'20". X 1,000.
Fig. 4. The cytotoxic activity of mouse AM 
       against 3LL by intravenous injection of 
       MDP-L 18 ; Dose-response relationship. 
       Groups of 4 mice were injected intraven-
      ously with different doses of MDP-L 18. 
       AM were harvested 24h after the injection 
       and were plated in culture wells. Next, 
       51Cr -labeled 3LL were added. All experi-
       ments were done in triplicate cultures. 
       Results are expressed as the mean ±SD 
       of three experiments.
CHM-LUV (MDP-L 18 10 ,u g per mouse). The 
cytotoxic activity of AM reached a maximum 
24 h after injection of the liposomes and 
decreased gradually with time, over the follow-
ing 48 hour period (Fig. 5). 
 In Vivo Activation of AM by MA-CDA. MA-
CDA itself had no cytolytic or cytostatic 
effect on 3LL in vitro (data not shown). Table 
1 shows that the cytostatic activity of AM 
increased as the effector (AM ) : target cell 
O LL) ratio was increased. As shown in Table 
2, the cytostatic activity of AM reached a 
maximum at three or five days after injection 
of MA-CDA, either nonencapsulated or 
encapsulated within liposomes. The activity of 
AM was highest in CHM-LUV (MA-CDA ) 
among the groups studied. Even at seven days 
after injection, the activity in CHM-LUV (MA-
CDA) was highest. These data demonstrate 
that MA-CDA encapsulated within CHM-LUV
Fig. 5. Kinetics of the cytotoxic activity of 
       mouse AM against 3LL by intravenous 
      injection of CHV-LUV containing MDP-
       L18 (10 g g/mouse ). AM were harvested 
       at various times after the injection and 
       were plated in culture wells. Next, 51Cr-
      labeled 3LL were added. All experiments 
       were done in triplicate cultures. Results 
       are expressed as the mean ±SD of three 
       experiments.
Table 1. Cytostatic activity of mouse alveolar 
        macrophages at different effector
        target ratios
                              cytostasisb) 
       Treatmenta) 
                    E/T 5 10 20 
PBS 6 8 18 
CHV-LUV (MA-CDA 1000 ,u g) 29 41 73 
Free MA-CDA 1000 ,u g 21 25 43
a) Groups of five mice were given intravenous 
injections of indicated materials. AM were harv-
ested five days later. 
b) All experiments were done in triplicate cul-
tures. 10 target cells were added to AM mono-
layer.
is more effective in the activation of AM 
than nonencapsulated MA-CDA. 
 Scanning Electron Microscopic Analysis of 
AM. Control (untreated) AM. After 24-h 
incubation on glass coverslips, most of the 
AM appeared more spherical than the activa-
ted AM, and were attached to coverslips by a 
small number of fine filopodia. A few AM 
were spread markedly over the coverslips. 
Furthermore, AM showed less surface activity
Table 2. Kinetics of the cytostatic activity of mouse alveolar macro-
        phages against 3LL by intravenous injection of MA-CDA
                                       cytostasisb) 
        Treatmenta) 
                          Day 1 Day 3 Day 5 Day 7 
PBS 4 16 16 15 
CHM-LUV (MA-CDA 1000 ,u g) 9 86c 77c 34c 
Free MA-CDA 1000 9 g 9 47 53 0 
empty CHM-LUV 10 13 12 8 
PBS 0 7 13 14 
CHM-LUV (MA-CDA 500,u g) 5 26d 36d 26d 
Free MA-CDA 500 9 g 4 12 20 8 
empty CHM-LUV ND* 10 9 ND
a) Groups of 5 mice were given intravenous injections of the indicated 
materials. AM were subsequently harvested at various times. 
b) All experiments were done in triplicate cultures. Data represents % 
cytostasis at effector/target cell ratio of 20 : 1. 
c) Statistically significant from Free MA-CDA 1000,ug, p<0.05. 
d) Statistically significant from Free MA-CDA 500,ug, p<O.01. 
* ND, not done.
than activated AM (Fig. 6). The control AM 
surface changed markedly with time in vitro : 
ruffles, lamellipodia, microvilli and filopodia 
disappeared after 48-h incubation (Fig. 7).
Fig. 7. Control AM fixed after 48-h culture. X 
      1,500.
Fig. 6. Control (untreated) AM fixed after 24-h 
       culture. X1,000.
 AM exposed to MA-CDA in vitro. AM 
morphologically resembled activated AM in 
vivo (Fig. 8), and these morphological changes 
were maintained for 72 h. However, AM
Fig. 8. AM cultured with MA-CDA 10 ,u g/ml in 
       vitro for 72h. X1,500.
activated by nonencapsulated MA-CDA in 
vitro had less cytostatic activity on 3LL than 
AM activated in vivo (data not shown) 
 Activated AM in vivo. AM harvested at 
three or five days after intravenous injection 
of nonencapsulated or encapsulated MA-CDA 
were more extensively spread over the cover-
slips and had a higher surface activity than 
control AM. Activated AM showed prominent 
ruffles, elongated filopodia, and thickened 
lamellipodia. It appeared that AM activated 
by encapsulated MA-CDA had higher surface 
activity than AM activated by nonencapsula-
ted MA-CDA (Fig. 9-11). 
 Interaction between activated AM and 
target cells. After 24-h incubation of activa-
ted AM and target cells, the coverslips were 
vigorously washed in order to separate the two 
types of cells. The attachment between the two 
cell types was so strong that vigorous washing 
could not separate them (Fig. 12). 
 Treatment of Tumor-Bearing Mice by CHM-
LUV (MA-CDA ). Pulmonary metastases 
were first observed at 10 to 12 days after 
inoculation of 3LL, and existed microscopi-
Fig. 9. Activated AM harvested three days after 
       intravenous injection of uncapsulated
   MA-CDA 1,000#g, 24-h culture. X1,000.
Fig. 10. Activated AM harvested three days after 
      intravenous injection of CHV-LUV (MA-
      CDA 1,000 g g) ; 24-h culture. X1,000.
cally at 14 days in most of the mice (data not 
shown). Results in Table 2 demonstrate that 
the cytostatic activity of AM in CHM-LUV 
(MA-CDA) was maintained for at least 5 days. 
 Next, inhibition of pulmonary metastases 
by CHM-LUV (MA-CDA) based on above 
results was attempted. A total dose of 3,000 
,u g MA-CDA per mouse was administered. The 
data of the survival experiment is shown in 
Fig. 13. Unfortunately, a difference in sur-
vival among the four treatment groups was 
not obtained, and all mice died of intrathor-
acic lymph node and multiple pulmonary meta-
stases within day 30 of the experiment.
Fig. 11. Activated AM harvested five days after 
      intravenous injection of CHM-LUV (MA-
       CDA 1,000 a g), 24-h culture. X 1,000.
Fig. 13. Survival of 3LL-bearing mice treated 
       with MA-CDA uncapsulated or encap-
       sulated within CHM-LUV. Total dose of 
       3,000 ,ug MA-CDA per mouse was
       administred after inoculation of 3LL.
Fig. 12. Attachment between activated AM (M) 
      and target cells (T). X3,000.
         DISCUSSION 
 This study demonstrated that immunoactiva-
tor (MDP-L 18 or MA-CDA) encapsulated with-
in polysaccharide-coated liposomes enhanced 
the antitumor activity of mouse AM more 
effectively than the nonencapsulated immuno-
activator (Fig. 4, Table 2 ). In addition, I 
reported, for the first time, that mouse AM 
had high surface activity upon treatment with 
synthetic polyanions such as MA-CDA, as 
visualized by scanning electron microscopy 
(Fig. 9-11). Macrophages activated by many 
types of immunoactivators for antitumor 
function have high antitumor activity, being 
specific for tumorigenic cells of any species 
(17-19). In the lung, AM plays an important 
role in defense against tumors (20). Therefore, 
it is advantageous to use AM activated by an
immunoactivator in the treatment of lung 
cancer. To date, there have been many studies 
using liposomes as drug carriers (2-5, 7-9), but 
few reports have employed immunoactivators 
encapsulated within liposomes in the treatment 
of cancer (6, 11). 
 For effective immunotherapy by AM target-
ing using liposomes, it is necessary for the 
liposomes to be engulfed by AM in vivo. In the 
present experiment, CHM-liposomes injected 
intravenously were obviously engulfed within 
AM (Fig. 2, 3, 4). However, LUV are unable 
to traverse the lung capillaries by themselves 
because of their large diameter (0.5-1.0 ,um). 
It is considered that LUV in the lung capillar-
ies were engulfed by circulating blood phago-
cytes which subsequently migrated to the 
alveoli to-become AM, as Poste et al. reported 
(21). Therefore, it is considered that there were 
many AM which had no cytoplasmic fluorescent 
foci in pulmonary lavage fluid. 
 It is well known that MDP, or its deriva-
tives, is capable of activating macrophages 
(22). Free MDP-L 18 injected intravenously did 
not lead AM to be cytotoxic at any doses rang-
ing from 0.01 to 100 u g per mouse (Fig. 4 ). In 
contrast, MDP-L 18 encapsulated within CHM-
LUV more than 1 ,u g enhanced the antitumor 
activity of AM. I speculate that the difference 
of the activation between free and encap-
sulated MDP-L 18 depends on whether MDP-
L 18 sufficiently pass into AM following 
intravenous injectivn. For this reason, most 
of free MDP-L 18 injected intravenously may 
be excreted within a short time before MDP-
L 18 pass into AM, and this short exposure 
of AM to MDP-L 18 may not be sufficient to 
activate AM. Parant et al reported that more 
than 5 0 % of 14 C-MDP was recovered in the 
urine after 30 min, and more than 90% after 
2 hours, following intravenous injection into 
mice (23). It was also proved, for the first 
time, that more than 24 hours are required to 
activate AM for antitumor function by encap-
sulated MDP-L 18, as shown in Fig. 5. 
 Polyanions have a broad range of biological 
activity including the ability to enhance host 
resistance against various microbial infections 
and cancer (24, 25). MA-CDA, which was used 
in this experiment, is also known to have the
same ability by activating macrophages (12, 
26). MA-CDA encapsulated within CHM-LUV 
enhanced the antitumor activity of mouse AM 
more effectively and for a longer period than 
nonencapsulated MA-CDA at the same dose 
(Table 2). The reason for this is that CHM-
LUV efficiently carried MA-CDA to the 
alveolar space, so that MA-CDA encapsulated 
within CHM-LUV activated AM for antitumor 
function. CHM-LUV themselves had no ability 
to activate AM, as shown in Table 2. It was 
also considered that a concentration of MA-
CDA sufficient to activate AM was maintain-
ed for several days by the encapsulation of 
MA-CDA within CHM-LUV. 
 It is interesting that a difference in time 
required to activate AM exists between en-
capsulated MDP-L 18 and MA-CDA. The 
difference may be due to a different process 
through which they activate AM, or a 
different mechanism involved in the destruc-
tion of tumor cells by activated AM. A 
resolution of its problem in the future can be 
expected. 
 Both in vivo and in vitro, mouse AM had 
very high surface activity due to MA-CDA 
such as prominent ruffles, elongated filopodia, 
and thickened lamellipodia. It is well known 
that the surface morphology of AM is changed 
by many kinds of agents (2 7, 2 8, 2 9) and 
cytokines (30), or some lung diseases (31). 
High surface activity may reflect activation 
of AM, but it does not always imply high 
antitumor activity. However, it was obvious 
in the case of MA-CDA that the antitumor 
activity of AM was related to high surface 
activity (Table 2, Figs 9-11). Futhermore, the 
attachment between activated AM and tumor 
cells was so strong that vigorous washing 
could not separate them (Fig. 12). It was 
clarified that macrophage-tumor binding 
might be one of mechanisms involved in the 
destruction of tumor cells by AM activated by 
MA-CDA. 
 I attempted inhibition of 3LL pulmonary 
metastasis by CHM-LUV (MA-CDA) based on 
the results shown in Table 2, but no prolonged 
survival was noted. Treatment of 3LL tumor-
bearing mice with MA-CDA alone was not 
successful in various protocols. For this
reason, it was considered that MA-CDA did 
not activate AM sufficiently enough to enable 
AM to kill 3LL cells as was expected. In the 
past several years, attention has been focused 
on polyanions' ability to stimulate increased 
myelopoiesis in normal mice (32). Schlick et 
al reported the usefulness of treatment with 
polyanions and cyclphosphamide in tumor-
bearing mice (33). It may be worthy to attempt 
future treatment with antineoplastic agents 
and CHM-LUV(MA- CDA). 
 In conclusion, I have reported that poly-
saccharide-coated liosomes containing immu-
notivators such as MDP-L 18 or MA-CDA 
activated AM for antitumor function to a 
greater extent and for a longer time than 
free immunoactivator, and also that . AM 
activated by MA-CDA encapsulated within 
these liposomes had high surface activity 
accompanied by antitumor activity. 
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